Chapter 10: Drug Repurposing as an Effective Solution to Control Salmonella Biofilm Infection Check Access

Salmonella biofilm infections continue to pose a problem in both clinical and environmental settings, necessitating novel treatment options. Traditional antibiotics frequently fail to eliminate biofilms owing to their intrinsic resistance mechanisms, resulting in persistent infections and major public health consequences. Drug repurposing, or the use of existing drugs for new therapeutic objectives, is a viable answer to this problem. This strategy takes advantage of current drugs’ known safety profiles and pharmacokinetic features to speed up the discovery of effective anti-biofilm therapy. Recent research has revealed numerous non-antibiotic medicines that show significant anti-biofilm efficacy against Salmonella spp. These chemicals were created to treat cancer, cardiovascular illnesses, and metabolic problems. Mechanistic studies suggest that these repurposed medicines interfere with quorum sensing, limit biofilm matrix development, and improve biofilm dispersion. Furthermore, combining repurposed medicines with traditional antibiotics has demonstrated synergistic benefits, greatly boosting treatment results. A recent study has found that a variety of non-antibiotic medications have strong anti-biofilm activity against Salmonella spp. These compounds were initially designed to treat cancer, cardiovascular disease, and metabolic issues. Mechanistic investigations indicate that these repurposed drugs disrupt quorum sensing, reduce biofilm matrix growth, and promote biofilm dispersion. Furthermore, combining repurposed medications with standard antibiotics has shown synergistic advantages, significantly improving treatment outcomes.